Enhanced Fluoropolymer Membrane Reactors for Production of Pharmaceutical Interme

用于生产药物中间体的增强型含氟聚合物膜反应器

• 批准号: 8256745
• 负责人: Andrew Feiring
• 金额: $ 19.81万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-15 至 2014-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8256745
• 关键词: Acetals; Acids; Acylation; Alcohols; Alkylation; Aromatic Compounds; Businesses; Carboxylic Acids; Chemicals; Environment; Esterification; Ethers; Excision; Fluorides; Industry; Liquid substance; Membrane; Minerals; Nature; Performance; Pharmacologic Substance; Polymers; Process; Production; Property; Reaction; Refuse Disposal; Relative (related person); Running; Safety; Schiff Bases; Security; Societies; Solid; Sulfonic Acids; System; Temperature; Waste Products; Water; catalyst; chemical stability; cold temperature; copolymer; cost; expectation; functional group; interest; ketal; microbial alkaline proteinase inhibitor; monomer; nitration; novel; programs; public health relevance; scale up; tetrafluoroethylene

DESCRIPTION (provided by applicant): The commercial syntheses of many pharmaceutical active ingredients and intermediates require acid catalysts and the removal of water to drive reactions to completion. Typical reactions include esterifications of carboxylic acids with alcohols, Friedel-Crafts acylations and alkylations, Schiff base, acetal and ketal formation and nitrations of aromatic compounds. Although common mineral acids are typically employed as catalysts, they create issues with product purification, waste disposal, safety, the environment and homeland security. Compact Membrane Systems, Inc. (CMS) proposes to develop membrane reactors (MR) to enhance these processes and eliminate the problems created by existing acid catalysts. CMS proposes developing enhanced membrane reactors and demonstrating performance on relevant pharmaceutical reactants. CMS has obtained key industry experts to facilitate this program. In this program, CMS will fabricate the membrane reactors. The resultant MR will be used to run reactions of pharmaceutical interest such as the alkylation and nitration of aromatic compounds. Expectation is that the CMS membrane reactor will result in higher yields, faster reactions and less contaminated products relative to incumbent processes and will have a very long lifetime due to the perfluorinated nature of the polymer. Society will benefit due to the lower production costs for the products, option for synthesis at lower temperature to maximize API efficacy, minimization of waste products and elimination of the transport and storage of strong mineral acids. PUBLIC HEALTH RELEVANCE: Project Narrative The use of catalytic membrane reactors can replace acid catalysts in the synthesis of pharmaceutical products at lower cost and higher processing throughput.

描述（由申请人提供）：许多药物活性成分和中间体的商业合成需要酸催化剂和去除水来驱动反应完成。典型的反应包括羧酸与醇的酯化、傅克酰化和烷基化、希夫碱、缩醛和缩酮形成以及芳香族化合物的硝化。尽管常见的无机酸通常用作催化剂，但它们会产生产品纯化、废物处理、安全、环境和国土安全方面的问题。 Compact Membrane Systems, Inc. (CMS) 提议开发膜反应器 (MR) 以增强这些工艺并消除现有酸催化剂产生的问题。 CMS 建议开发增强型膜反应器并展示相关药物反应物的性能。 CMS 已聘请重要的行业专家来推动该计划。在此计划中，CMS 将制造膜反应器。所得的 MR 将用于运行具有制药意义的反应，例如芳香族化合物的烷基化和硝化。预计 CMS 膜反应器相对于现有工艺将产生更高的产率、更快的反应和更少的污染产品，并且由于聚合物的全氟化性质，将具有非常长的使用寿命。由于产品生产成本较低、可以在较低温度下合成以最大限度地提高 API 功效、最大限度地减少废物以及消除强无机酸的运输和储存，社会将从中受益。 公共卫生相关性：项目叙述 使用催化膜反应器可以以更低的成本和更高的处理量替代药品合成中的酸催化剂。